Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade for Iron Overload Post-HSCT
NCT01159067Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Jul 2010
- Primary completion
- Aug 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of deferasirox in iron overload, sponsored by City of Hope. Primary endpoint: Number of Patients With Elevated Labile Plasma Iron Above Threshold (0.5 Umol/L). Started Jul 2010; status: terminated.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT01159067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01159067.